BC Week In Review | Oct 22, 2012
Clinical News

RPL554: Phase I/IIa data

A double-blind, Dutch Phase I/IIa trial in 18 healthy volunteers in and 16 patients with asthma showed that single ascending-doses of 0.003-0.018 mg/kg RPL554 were well tolerated with no significant changes in heart rate or...
BC Innovations | Jun 28, 2012

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program ( see "Repurposing pharma compounds"). The compounds provided by...
BioCentury | Apr 9, 2012

A longer weight

FDA may be on the verge of approving the first new obesity drug in more than a decade - Qnexa phentermine/topiramate from Vivus Inc. But it could be another five to six years before next-generation compounds...
BC Week In Review | Oct 24, 2011
Clinical News

ALB-127158: Development discontinued

Albany Molecular said it will discontinue development of ALB-127158(a) after an analysis of cerebrospinal fluid (CSF) data from an open-label, U.K. Phase I trial in 9 healthy volunteers suggested that a higher than predicted dose...
BC Week In Review | Jun 20, 2011
Clinical News

ALB-127158: Phase I data

A double-blind, placebo-controlled, U.K. Phase I trial showed that oral ALB-127158(a) was well tolerated and reduced parameters of hunger, the desire to eat and meal consumption. Additionally, there were no treatment-related changes in cardiovascular parameters...
BioCentury | Feb 7, 2011
Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc. 's Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be...
BC Innovations | Aug 12, 2010
Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche 's Genentech Inc. unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease. 1 Nineteen of the 112 candidate...
BC Week In Review | Aug 2, 2010
Clinical News

ALB-127158: Phase I started

Albany Molecular began a double-blind, placebo-controlled, dose-escalation, U.K. Phase I trial to evaluate oral ALB-127158(a) in 62 healthy volunteers and patients. The 2-part study will initially evaluate single ascending doses of ALB-127158(a) in healthy volunteers...
BC Week In Review | Oct 12, 2009
Company News

Epix deal

Epix Pharmaceuticals Inc. (Pink:EPIX), Lexington, Mass.   Business: Neurology   Five undisclosed companies purchased the IP related to five undisclosed Epix assets at auction. Epix, which decided to wind down its operations and transferred all...
BC Innovations | Apr 2, 2009
Distillery Techniques

Technology: Computational models

This week in techniques Approach Summary Licensing status Publication and contact information Computational models Identification of chemically feasible molecular fragments to aid in drug discovery A computational tool that analyzes molecular fragments could aid in...
Items per page:
1 - 10 of 32